Post-grant proceedings: shaping the biotech landscape
In March 2010, the Biologics Price Competition and Innovation Act (BPCIA) created an abbreviated pathway for licensing biosimilars and a 12-year exclusivity period for first licensed biologics. Shortly after, the America Invents Act (AIA) provided multiple changes to the patent system and established a variety of post-grant proceedings. Notably, the AIA established post-grant review (PGR) proceedings and inter partes review (IPR) proceedings.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
5 May 2026 J&J’s Abiomed can proceed with its non-infringement defence despite potential future appellate reversal, in a week when both parties in the case were dealt wins and losses in their clash over Impella devices.
4 May 2026 LSIPR's senior reporter Marisa Woutersen speaks with Ben Doranz of Integral Molecular, fresh from the stage at LSPN Boston after speaking at a panel session on challenges in antibody patent protection.
1 May 2026 The Office of the US Trade Representative has placed the EU on its Watch List, outlining concerns about pharma legislation, GIs and digital copyright.